Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.54 |
| ▸ | EBP | Q15125 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578498 | 0.90 | SIGMAR1 (0.48) | SIGMAR1EBPOPRL1CHRM3TSHR | |
| SCHEMBL5578791 | 0.89 | SIGMAR1 (0.57) | SIGMAR1EBPOPRL1OPRK1 | |
| SCHEMBL5578636 | 0.87 | SIGMAR1 (0.55) | SIGMAR1OPRL1OPRK1CHRM3 | |
| SCHEMBL5578548 | 0.82 | SIGMAR1 (0.49) | SIGMAR1EBP | |
| SCHEMBL5580165 | 0.80 | SIGMAR1 (0.52) | SIGMAR1EBPOPRL1OPRK1 | |
| SCHEMBL5579023 | 0.80 | SIGMAR1 (0.55) | SIGMAR1EBPOPRL1OPRK1 | |
| SCHEMBL5578840 | 0.78 | DPP9 (0.44) | TSHR | |
| SCHEMBL5578976 | 0.78 | ATM (0.46) | TSHR | |
| SCHEMBL5578859 | 0.77 | HDAC1 (0.46) | SIGMAR1TSHR | |
| SCHEMBL5579055 | 0.76 | SIGMAR1 (0.49) | SIGMAR1OPRL1CHRM3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | claimed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | claimed |
| EP-1716148-A2 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2005063745-A2 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | SIGMAR1 444/4885EBP 1262/4885OPRL1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.